Featured Story | By Nick Paul Taylor Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to buy the system outright. read more |
| |
|---|
|
|  | eBook: Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including larger molecules and novel indications. She also discusses changes within CDMOs and various challenges facing the industry. Learn more about trends in orally and nasally inhaled therapeutics, new avenues for existing dose forms, and industry response to OINDP trends. Download Now. |
|---|
Top Stories By Nick Paul Taylor Advanz Pharma secured rights to Polypid’s prolonged-release antibiotic candidate D-PLEX100, paying $2.6 million upfront and dangling more than $100 million in milestones to secure the European license. read more By Nick Paul Taylor The Biomedical Advanced Research and Development Authority (BARDA) is providing further funding to Opiant Pharmaceuticals, coughing up $2.1 million to support the preparation and filing of an application for approval of OPNT003. read more By Nick Paul Taylor Systemically delivered checkpoint inhibitors have grown into the cornerstone of immuno-oncology. Now, a team at the Terasaki Institute for Biomedical Innovation in Los Angeles wants to improve the effects of the molecules through local delivery. read more By Angus Liu The seemingly unstoppable pharma lobbying power has lost its charm. As the U.S. Senate opens the door to a major drug pricing reform with passage of a new bill, the drug industry is licking its wounds. read more By Fraiser Kansteiner Given the nature of warning letters and 483s as well as the dangers tied to manufacturing snafus, it doesn't make sense to rank worst offenders. Instead, we're providing a glimpse of FDA write-ups that are significant for different reasons. read more By Teresa Carey This week on "The Top Line," we explore why many early pandemic therapeutics are now throwing in the towel. We also chat about earnings season, and how biotechs' pipelines have changed, even the stuff that companies are less keen to talk about. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
